Induction of Acute Myeloid Leukemia with Idarubicin, Cytarabine and Cladribine.
BACKGROUND
Daunorubicin and cytarabine has been the standard-of-care for induction therapy for acute myeloid leukemia (AML). Adding cladribine to daunorubicin (60 mg/m(2)) and cytarabine has increased complete remission (CR) rates and median overall survival (OS). However, the efficacy of adding cladribine to 7+3 with other anthracyclines is unknown.


METHODS
We retrospectively evaluated patients with AML receiving induction with idarubicin, cytarabine and cladribine (ICC) between 1/1/2010 and 06/30/2015 at the Methodist University Hospital in Memphis, Tennessee. Institutional Review Board approval was obtained for the study. Patient, disease characteristics and outcomes were analyzed with GraphPad Prism, Microsoft Excel and SPSSv19.0 software.


RESULTS
Twenty-four patients induced with ICC for AML were identified. Thirteen (54.2%) had at least one high-risk feature. Hypoplastic marrow was achieved in all by day 14; 19 (79.2%) achieved CR. Thirty-day mortality was 8.3%; 33-month OS and disease-free survival were 56% and 36%, respectively.


CONCLUSIONS
Induction of AML with ICC was associated with a high CR rate and OS in our high-risk population.
Department of Hematology/Oncology, The West Clinic, Memphis, TN, U.S.A.
Eric
E
Wiedower
Department of Internal Medicine, The University of Tennessee Health Science Center, Memphis, TN, U.S.A. omerjamy@gmail.com.
Omer
O
Jamy
Department of Hematology/Oncology, The West Clinic, Memphis, TN, U.S.A.
Michael G
MG
Martin
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017338:Cladribine / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D012074:Remission Induction; D012189:Retrospective Studies; D015996:Survival Rate; D055815:Young Adult
D003561:Cytarabine; D017338:Cladribine; D015255:Idarubicin; D003630:Daunorubicin
Acute myeloid leukemia; cladribine; idarubicin; induction